MPS II

MPS II

MPS II

abbreviation for mucopolysaccharidosis II. See Hunter's syndrome.
References in periodicals archive ?
later this year for the SB-FIX Phase 1/2 clinical trial and to file additional CTAs for its SB-318 and SB-913 in vivo genome editing treatments for Mucopolysaccharidosis Type I and MPS II, respectively.
M2 PHARMA-February 12, 2018-Initial Safety Data from Sangamo Therapeutics Genome Editing Study for MPS II Presented at WORLDSymposium
25 January 2018 - UK-based technology group Elektron Technology plc's (AIM: EKT) Elektron Eye Technology business has purchased the patent of the MPS II macular pigment screening device for the sum of GBP 220,000 (USD 314,320), the group said.
On Monday, in a medical first, Brian Madeux received an experimental in-body gene-editing treatment intended to cure him of Mucopolysaccharidoses II, known as MPS II or Hunter syndrome, a rare disorder that causes progressive damage to the body's cells.
This year Sangamo is conducting the first ever in vivo genome editing clinical trials evaluating ZFN-mediated therapeutic genome editing approaches for the treatment of hemophilia B, a rare blood disorder, and two rare lysosomal storage disorders, MPS I and MPS II.
Therapies are available for only 6 LSDs - Gaucher, Pompe, Fabry, Mucopolysaccharidosis (MPS) I (Hurler syndrome), MPS II (Hunter Syndrome) and MPS VI (MaroteauxLamy)," said Prof.
The MPS II sensillum was more slender and longer than the MPS I sensillum, slightly curved, with a smooth surface; and the average length and width of various MPS II sensilla varied from 37.
BiB Ophthalmic Instruments has been appointed as an approved distributor of the new MPS II Macula Pigment Screener (pictured), manufactured by Elektron Technology.
Currently therapies are available for only 6 LSDs - Gaucher, Pompe, Fabry, Mucopolysaccharidosis (MPS) I (Hurler syndrome), MPS II (Hunter Syndrome) and MPS VI (MaroteauxLamy).
A MPS II, tambem chamada de Sindrome de Hunter, pode ser classificada como leve ou grave, de acordo com o comprometimento do sistema nervoso central [3-5].
At the age of six, Chris was diagnosed with MPS II Hunter syndrome and told that he would not live past age 18.
Mecanismo Doencaalvo Nome do farmaco de acao Fabry Betagalsidase TRE Fabry Alfagalsidase TRE Fabry AT1001 Chaperona Gaucher Velaglucerase alfa (glicocerebrosidase TRE produzida em celulas humanas) Gaucher Glicocerebrosidase produzida em TRE celulas vegetais Gaucher Miglustate ISS Gaucher Genz-112638 ISS Gaucher AT2101 Chaperona MPS I Laronidase TRE MPS II Idursulfase TRE MPS VI Galsulfase TRE Niemann-Pick B Esfingomielinase recombinante TRE Niemann-Pick C Miglustate ISS Pompe Alglucosidase alfa([alpha]-glicosidase TRE acida produzida em celulas CHO) Pompe [alfa]-glicosidase acida recombinante TRE produzida a partir do leite de coelhos transgenicos Tay-Sachs (tardia) Miglustate ISS Tay-Sachs (tardia) Pirimetamina Chaperona Registro Doencaalvo Fase de desenvolvimento Anvisa?